



*Two Week extension under exceptional consideration (delayed labs, drug wash out, COVID-19-related delays) with Medical Monitor approval.

FIG. 1



equiv. = equivalent; HZN7734 = also known as daxdilimab (previously VIB7734 or HZN-7734); N = number of subjects; OGC = oral glucocorticoid; Q12W = every 12 weeks; RECAST SLE = Phase 2 **R**andomized, Double-Blind, Placebo-Controlled **E**ffi**ca**cy and **S**afety Study of Daxdilimab for the **T**reatment of Moderate to Severely Active **S**ystemic **L**upus **E**rythematosus; SC = subcutaneous(ly); W = week.

FIG. 2

Visit	Dose of Oral Prednisone or Equivalent at Start of Study [a]				
Week 0	40 mg	30 mg	20 mg	10 mg	7.5 mg [b]
Week 4	30 mg	22.5 mg	15 mg	7.5 mg	5 mg
Week 8	20 mg	15 mg	10 mg	5 mg	4 mg
Week 12	12.5 mg	10 mg	7.5 mg	4 mg	3 mg
Week 16	7.5 mg	7.5 mg	5 mg	3 mg	2 mg
Week 20	5 mg	5 mg	4 mg	2 mg	1 mg
Week 24	4 mg	4 mg	3 mg	1 mg	Discontinue
Week 28	3 mg	3 mg	2 mg	Discontinue	Discontinue
Week 32	2 mg	2 mg	1 mg	Discontinue	Discontinue
Week 36	1 mg	1 mg	Discontinue	Discontinue	Discontinue
Week 40	Discontinue	Discontinue	Discontinue	Discontinue	Discontinue
Week 44	Discontinue	Discontinue	Discontinue	Discontinue	Discontinue
Week 48	Discontinue	Discontinue	Discontinue	Discontinue	Discontinue


OGC = oral glucocorticoid

The OGC tapering schedule represents an example of a tapering regimen to provide guidance to Investigators in the approach to steroid taper throughout the study with the aim to lower the daily dose OGC to total discontinuation if clinically possible throughout the study.

a Specified prednisone dose is dose at the beginning of the week.


b Subjects entering study at < 7.5 mg/day dose of OGC must taper until full discontinuation if clinically possible. It is encouraged that Investigators taper each month by at least 1 mg/day.

FIG. 3



Abbreviations: SC, subcutaneously; Q4W, every 4 weeks; WK, week.


FIG. 4



Olsen/Canfield

Left Quadrant Raw Score (LRS)		Top Quadrant Raw Score (TRS)	
Right Quadrant Raw Score (RRS)		Back Quadrant Raw Score (BRS)	
Total SALT Score [(LRS x 0.18) + (RRS x 0.18) + (TRS x 0.40) + (BRS x 0.24)]			

FIG. 5



Olsen/Canfield

FIG. 6



W0, D1
Stratification & Randomization
W0, D1
Methylprednisolone dose: 500 mg (prior to receiving IP)
OCS: oral prednisone (or equivalent) dosed at 0.5 mg/kg/day during Screening or at Day 1 (daily maximum dose of prednisone is 40 mg)
W0 through W8
One additional methyl-prednisolone pulse permitted
W40 through W52
NO STEROID TAPERING PERMITTED
(stable MMF/MFA & OCS dose)
W92 through W104
NO STEROID TAPERING PERMITTED
(stable MMF/MFA & OCS dose)
Week
0 2 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 104 112
IP/PBO Administration
Screening Period (4 weeks)
(D-28 to D-1)
Treatment Period (104 weeks)
Arm 1 (n=70):
Day 1 through Week 52: Daxdilimab 100 mg SC at D1, W2, and W4, followed by 100 mg SC Q4W through W52 + SOC
Week 64 through Week 104: • PBR (or CBR) at both W48 and W52: daxdilimab 100 mg SC Q12W through W104 (last dose at W100) OR • No PBR (or CBR) at either W48 or W52: daxdilimab 300 mg SC Q12W through W104 (last dose at W100)
Arm 2 (n=70):
Day 1 through Week 52: Daxdilimab 300 mg SC at D1, W2, and W4, followed by 300 mg SC Q4W through W52 + SOC
Week 64 through Week 104: • PBR (or CBR) at both W48 and W52: daxdilimab 300 mg SC Q12W through W104 (last dose at W100) OR • No PBR (or CBR) at either W48 or W52: daxdilimab 300 mg SC Q12W through W104 (last dose at W100)
Arm 3 (n=70):
Day 1 through Week 52: Placebo SC at D1, W2, and W4, followed by placebo SC Q4W through W52 + SOC
Week 64 through Week 104: • PBR (or CBR) at both W48 and W52: placebo SC Q12W through W104 (last dose at W100) OR • No PBR (or CBR) at either W48 or W52: daxdilimab 300 mg SC Q12W through W104 (last dose at W100)
Safety Follow-Up Period (8 weeks)
End-of-Study Visit W112
= IP/PBO administration
= OCS target dose of prednisone/prednisone equivalent
Week 12: ≤7.5 mg/day
Week 24: ≤2.5 mg/day
= Primary Endpoint

FIG. 7



Screening (Days -28 to -1)
Daxdilimab Administration and Safety/Efficacy Assessments (Day 1 to Week 24)
Follow-up Daxdilimab Administration and Additional Safety/Efficacy Assessments (Weeks 28 to 56)
Group 1: Placebo SC Q4W; N = 33
Daxdilimab 300 mg SC Q4W
Group 2: Daxdilimab 150 mg SC Q4W; N = 33
Group 3: Daxdilimab 300 mg SC Q4W; N = 33
Time (Weeks)
Q4W Dosing
Day 1
4
8
12
16
20
24
28
32
36
40
44
48
52
56
Primary Efficacy Assessment
Optional OLE
SFU

FIG. 8